Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06388551
PHASE1

A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017

Sponsor: Luye Pharma Group Ltd.

View on ClinicalTrials.gov

Summary

This is a phase 1,randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects.

Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, SAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral LPM526000133 Fumarate Capsules (LY03017) in Healthy Adult Subjects.

Key Details

Gender

All

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2024-05-10

Completion Date

2025-03-30

Last Updated

2024-04-29

Healthy Volunteers

Yes

Interventions

DRUG

LY03017

single dose, administered orally

DRUG

LY03017-Placebo

single dose, administered orally

Locations (1)

Shanghai Mental Health Center

Shanghai, China